The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Multiple Myeloma · Smoldering Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Oslo Myeloma Center, Oslo, Oslo, Norway
Contact: Study coordinator (Fredrik B Schjesvold, MD, PhD) · fredrikschjesvold@gmail.com · 996 97 796
Contact: Study coordinator (Hanne M Norseth, MD) · h.m.norseth@gmail.com · 92847595

Study leads

Fredik Schjesvold, MD PhD
Principal Investigator
Oslo Myeloma Center, Oslo University Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Detroit, United States · Lansing, United States

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma · Cancer

Abroad (travel likely)RecruitingPHASE2

Chapel Hill, United States · Charlotte, United States

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

B-Cell Non-Hodgkin Lymphoma · Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Duarte, United States

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Multiple Myeloma · Lymphoma

Abroad (travel likely)RecruitingPHASE2

Hefei, China · Beijing, China